GlassScriptPhysician profile
Bartel R Crisafi
NPI 1124079090
$2,976.61
in general payments reported to CMS, 2019-2025
19 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $169 · 2021: $201 · 2022: $428 · 2023: $625 · 2024: $779 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $966.51 | 2019-2025 | Ubrelvy |
| Lilly USA, LLC | $392.96 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $304.65 | 2019-2025 | Farxiga, Fasenra |
| Allergan, INC. | $290.93 | 2019-2020 | |
| Glaxosmithkline, LLC. | $214.02 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $160.92 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $143.41 | 2023-2025 | |
| Amgen INC. | $84.28 | 2019-2024 | Otezla, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $81.07 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $59.71 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $53.25 | 2023-2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $50.57 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.21 | 2019-2025 | Ofev |
| Merck Sharp & Dohme LLC | $34.99 | 2023 | M-M-R II, Gardasil 9, Pneumovax 23 |
| Ars Pharmaceuticals Operations, INC. | $27.81 | 2025 | Neffy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.72 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $16.48 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $14.87 | 2020 | |
| Shire North American Group INC | $14.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bartel Crisafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.